NextCure, Inc. Common Stock NXTC
Key Stats
- Today's Range
- $4.95 – $6.00
- 50-Day Range
- $1.55 – $9.90
- 52-Week Range
- $1.55 – $15.74
- Volume
- 230K shs
- Average Volume
- 4.31 million shs
- Market Cap
- $21.36 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.80
- Price / Sales
- —
Short Interest
- Short Interest
- 0.05%
- Days to Cover
- 1.00
Financials (TTM)
- Revenue
- —
- Net Income
- $-54,664,000
- Net Margin
- —
- Return on Equity
- -204.61%
- Debt-to-Equity
- —
About NextCure, Inc. Common Stock
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
Related Stocks
Compare head-to-head: NXTC vs LLY·NXTC vs JNJ·NXTC vs ABBV·NXTC vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.